Product Reports Resources Pricing Login Book a demo

Hervolution Therapeutics

Biotech & Life Sciences · Copenhagen, Denmark · Founded 2011

Immunotherapies targeting dark genome HERV antigens. MoreLess

Operator of a biotechnology company intended to treat cancer by targeting tumor viruses within the human genome. The company offers broad and curative cancer therapy in combination with immune checkpoint inhibitors, enabling medical researchers to easily find treatment for cancer using adaptive immune therapy.

Talent graph

Hervolution Therapeutics's talent

Book a demo to see the people
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on Hervolution Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage
European Innovation Council
Series A 2 investors entered at this stage
EIC Fund
Serum Institute of India

Global footprint

Where Hervolution Therapeutics has talent and traffic

Workforce by country
7 countries with
team presence
🇩🇰 Denmark76.7%
🇺🇸 United States6.7%
🏳️ Andorra3.3%
🇦🇹 Austria3.3%
🇦🇺 Australia3.3%
Top 5 of 7 shown

Market sentiment

What the market is saying about Hervolution Therapeutics

An AI-synthesized read of the highest-engagement posts about Hervolution Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hervolution Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.